BACKGROUND Although transmembrane protein 106C(TMEM106C)has been elucidated to be overexpressed in cancers,its underlying mechanisms have not yet been fully understood.AIM To investigate the expression levels and mole...BACKGROUND Although transmembrane protein 106C(TMEM106C)has been elucidated to be overexpressed in cancers,its underlying mechanisms have not yet been fully understood.AIM To investigate the expression levels and molecular mechanisms of TMEM106C across 34 different cancer types,including liver hepatocellular carcinoma(LIHC).METHODS We analyzed TMEM106C expression patterns in pan-cancers using microenvironment cell populations counter to evaluate its association with the tumor microenvironment.Gene set enrichment analysis was conducted to identify molecular pathways related to TMEM106C.Chromatin immunoprecipitation followed by sequencing(ChIP-seq)analysis was conducted to identify upstream transcriptional regulators of TMEM106C.In LIHC,we examined mRNA profiles,performed in-house quantitative polymerase chain reaction,immunohistochemistry,and constructed a co-expression gene network.Functional assays,including cell counting kit-8,cell cycle,apoptosis,migration,and invasion,were conducted.The effect of nitidine chloride(NC)on LIHC xenograft was evaluated through RNA sequencing and molecular docking.Finally,potential therapeutic agents targeting TMEM106C were predicted.RESULTS TMEM106C was significantly overexpressed in 27 different cancer types and presaged poor prognosis in four of these types,including LIHC.Across pan-cancers,TMEM106C was inversely correlated to the abundances of immune and stromal cells.Furthermore,TMEM106C was significantly linked to cell cycle and DNA replication pathways in pan-cancers.ChIP-seq analysis predicted CCCTC-binding factor as a pivotal transcriptional factor targeting the TMEM106C gene in pan-cancers.Integrated analysis showed that TMEM106C was upregulated in 4657 LIHC compared with 3652 normal liver tissue[combined standardized mean difference=1.31(1.09,1.52)].Inhouse LIHC samples verified the expression status of TMEM106C.Higher TMEM106C expression signified worse survival conditions in LIHC patients treated with sorafenib,a tyrosine kinase inhibitor(TKI).Co-expressed analysis revealed that TMEM106C were significantly enriched in the cell cycle pathway.Knockout experiments demonstrated that TMEM106C plays a crucial role in LIHC cell proliferation,migration,and invasion,with cell cycle arrest occurring at the DNA synthesis phase,and increased apoptosis.Notably,TMEM106C upregulation was attenuated by NC treatment.Finally,TMEM106C expression levels were significantly correlated with the drug sensitivity of anti-hepatocellular carcinoma agents,including JNJ-42756493,a TKI agent.CONCLUSION Overexpressed TMEM106C was predicted as an oncogene in pan-cancers,which may serve as a promising therapeutic target for various cancers,including LIHC.Targeting TMEM106C could potentially offer a novel direction in overcoming TKI resistance specifically in LIHC.Future research directions include in-depth experimental validation and exploration of TMEM106C’s role in other cancer types.展开更多
目的探讨血清微小RNA(miRNA)-106a和miRNA-20a水平与新生儿呼吸窘迫综合征(NRDS)严重程度及预后的相关性。方法选取2021年3月至2024年4月在西安交通大学附属红会医院就诊的156例NRDS患儿为NRDS组,其中男77例,女79例,出生胎龄(33.87±...目的探讨血清微小RNA(miRNA)-106a和miRNA-20a水平与新生儿呼吸窘迫综合征(NRDS)严重程度及预后的相关性。方法选取2021年3月至2024年4月在西安交通大学附属红会医院就诊的156例NRDS患儿为NRDS组,其中男77例,女79例,出生胎龄(33.87±2.01)周。根据NRDS患儿胸部影像检查结果将其分为轻度组(50例)、中度组(74例)和重度组(32例)。根据NRDS患儿结局将其分为预后良好组132例和预后不良组24例。另选取同期在西安交通大学附属红会医院体检的健康早产儿150例作为对照组,其中男77例,女73例,出生胎龄(34.05±1.83)周。采用定量聚合酶链式反应(qPCR)测定血清miRNA-106a和miRNA-20a水平;采用Pearson相关分析NRDS患儿血清miRNA-106a和miRNA-20a水平与新生儿急性生理评分(SNAPPE-Ⅱ)、1 min Apgar评分的相关性;采用受试者操作特征曲线(ROC)评价血清miRNA-106a和miRNA-20a水平预测NRDS患儿预后的价值。采用t检验、χ^(2)检验。结果NRDS组患儿血清miRNA-106a和miRNA-20a水平低于对照组[(0.97±0.30)比(1.70±0.53)、(0.88±0.32)比(1.57±0.55)],差异均有统计学意义(t=14.750、13.346,均P<0.05)。重度组、中度组、轻度组血清miRNA-106a和miRNA-20a水平及1 min Apgar评分比较,差异均有统计学意义(均P<0.05)。预后不良组NRDS患儿血清miRNA-106a和miRNA-20a水平低于预后良好组[(0.40±0.19)比(1.07±0.36)、(0.39±0.17)比(0.97±0.34)],SNAPPE-Ⅱ评分高于预后良好组[(34.25±6.50)分比(18.10±3.58)分],差异均有统计学意义(t=13.438、12.718、11.850,均P<0.05)。血清miRNA-106a和miRNA-20a水平与SNAPPE-Ⅱ评分呈负相关(均P<0.05),与1 min Apgar评分呈正相关(均P<0.05)。miRNA-106a、miRNA-20a预测NRDS患儿预后不良的灵敏度分别为95.8%、91.7%,特异度分别为93.2%、89.4%,曲线下面积(AUC)分别为0.961(95%CI 0.929~0.992)、0.938(95%CI 0.900~0.976),表明这些生物标志物预测NRDS患儿预后准确度较高。miRNA-106a联合miRNA-20a的灵敏度和特异度分别为91.7%、97.7%,AUC为0.984(95%CI 0.967~1.000),表明联合检测具有更高的预测效能。结论血清miRNA-106a和miRNA-20a水平在NRDS患儿中降低,且其水平随NRDS患儿严重程度加重而逐渐降低,二者在预测NRDS患儿预后中具有重要价值。展开更多
基金Supported by the National Natural Science Foundation of China,No.NSFC82160762,No.NSFC82460783Natural Science Foundation of Guangxi,No.2022GXNSFBA035657Innovation Project of Guangxi Graduate Education,No.JGY2023068,No.YCSW2023220.
文摘BACKGROUND Although transmembrane protein 106C(TMEM106C)has been elucidated to be overexpressed in cancers,its underlying mechanisms have not yet been fully understood.AIM To investigate the expression levels and molecular mechanisms of TMEM106C across 34 different cancer types,including liver hepatocellular carcinoma(LIHC).METHODS We analyzed TMEM106C expression patterns in pan-cancers using microenvironment cell populations counter to evaluate its association with the tumor microenvironment.Gene set enrichment analysis was conducted to identify molecular pathways related to TMEM106C.Chromatin immunoprecipitation followed by sequencing(ChIP-seq)analysis was conducted to identify upstream transcriptional regulators of TMEM106C.In LIHC,we examined mRNA profiles,performed in-house quantitative polymerase chain reaction,immunohistochemistry,and constructed a co-expression gene network.Functional assays,including cell counting kit-8,cell cycle,apoptosis,migration,and invasion,were conducted.The effect of nitidine chloride(NC)on LIHC xenograft was evaluated through RNA sequencing and molecular docking.Finally,potential therapeutic agents targeting TMEM106C were predicted.RESULTS TMEM106C was significantly overexpressed in 27 different cancer types and presaged poor prognosis in four of these types,including LIHC.Across pan-cancers,TMEM106C was inversely correlated to the abundances of immune and stromal cells.Furthermore,TMEM106C was significantly linked to cell cycle and DNA replication pathways in pan-cancers.ChIP-seq analysis predicted CCCTC-binding factor as a pivotal transcriptional factor targeting the TMEM106C gene in pan-cancers.Integrated analysis showed that TMEM106C was upregulated in 4657 LIHC compared with 3652 normal liver tissue[combined standardized mean difference=1.31(1.09,1.52)].Inhouse LIHC samples verified the expression status of TMEM106C.Higher TMEM106C expression signified worse survival conditions in LIHC patients treated with sorafenib,a tyrosine kinase inhibitor(TKI).Co-expressed analysis revealed that TMEM106C were significantly enriched in the cell cycle pathway.Knockout experiments demonstrated that TMEM106C plays a crucial role in LIHC cell proliferation,migration,and invasion,with cell cycle arrest occurring at the DNA synthesis phase,and increased apoptosis.Notably,TMEM106C upregulation was attenuated by NC treatment.Finally,TMEM106C expression levels were significantly correlated with the drug sensitivity of anti-hepatocellular carcinoma agents,including JNJ-42756493,a TKI agent.CONCLUSION Overexpressed TMEM106C was predicted as an oncogene in pan-cancers,which may serve as a promising therapeutic target for various cancers,including LIHC.Targeting TMEM106C could potentially offer a novel direction in overcoming TKI resistance specifically in LIHC.Future research directions include in-depth experimental validation and exploration of TMEM106C’s role in other cancer types.
文摘目的探讨血清微小RNA(miRNA)-106a和miRNA-20a水平与新生儿呼吸窘迫综合征(NRDS)严重程度及预后的相关性。方法选取2021年3月至2024年4月在西安交通大学附属红会医院就诊的156例NRDS患儿为NRDS组,其中男77例,女79例,出生胎龄(33.87±2.01)周。根据NRDS患儿胸部影像检查结果将其分为轻度组(50例)、中度组(74例)和重度组(32例)。根据NRDS患儿结局将其分为预后良好组132例和预后不良组24例。另选取同期在西安交通大学附属红会医院体检的健康早产儿150例作为对照组,其中男77例,女73例,出生胎龄(34.05±1.83)周。采用定量聚合酶链式反应(qPCR)测定血清miRNA-106a和miRNA-20a水平;采用Pearson相关分析NRDS患儿血清miRNA-106a和miRNA-20a水平与新生儿急性生理评分(SNAPPE-Ⅱ)、1 min Apgar评分的相关性;采用受试者操作特征曲线(ROC)评价血清miRNA-106a和miRNA-20a水平预测NRDS患儿预后的价值。采用t检验、χ^(2)检验。结果NRDS组患儿血清miRNA-106a和miRNA-20a水平低于对照组[(0.97±0.30)比(1.70±0.53)、(0.88±0.32)比(1.57±0.55)],差异均有统计学意义(t=14.750、13.346,均P<0.05)。重度组、中度组、轻度组血清miRNA-106a和miRNA-20a水平及1 min Apgar评分比较,差异均有统计学意义(均P<0.05)。预后不良组NRDS患儿血清miRNA-106a和miRNA-20a水平低于预后良好组[(0.40±0.19)比(1.07±0.36)、(0.39±0.17)比(0.97±0.34)],SNAPPE-Ⅱ评分高于预后良好组[(34.25±6.50)分比(18.10±3.58)分],差异均有统计学意义(t=13.438、12.718、11.850,均P<0.05)。血清miRNA-106a和miRNA-20a水平与SNAPPE-Ⅱ评分呈负相关(均P<0.05),与1 min Apgar评分呈正相关(均P<0.05)。miRNA-106a、miRNA-20a预测NRDS患儿预后不良的灵敏度分别为95.8%、91.7%,特异度分别为93.2%、89.4%,曲线下面积(AUC)分别为0.961(95%CI 0.929~0.992)、0.938(95%CI 0.900~0.976),表明这些生物标志物预测NRDS患儿预后准确度较高。miRNA-106a联合miRNA-20a的灵敏度和特异度分别为91.7%、97.7%,AUC为0.984(95%CI 0.967~1.000),表明联合检测具有更高的预测效能。结论血清miRNA-106a和miRNA-20a水平在NRDS患儿中降低,且其水平随NRDS患儿严重程度加重而逐渐降低,二者在预测NRDS患儿预后中具有重要价值。
